PID's Holdings Imply 14% Gain Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2024
0mins
Source: NASDAQ.COM
Invesco International Dividend Achievers ETF Analysis: The Invesco International Dividend Achievers ETF (PID) has an implied analyst target price of $21.89 per unit, indicating a potential upside of 14.36% from its recent trading price of $19.14.
Notable Holdings and Analyst Targets: Key holdings such as National Grid plc, Restaurant Brands International Inc, and Novartis AG show significant upside potential, with target prices suggesting increases of 28.92%, 20.28%, and 19.45% respectively compared to their current share prices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 151.970
Low
112.00
Averages
127.75
High
143.00
Current: 151.970
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Dividend Stocks in the Pharmaceutical Industry
- Merck's Challenges and Opportunities: Despite declining sales of its HPV vaccines due to issues in Asia, Merck's Keytruda remains the world's best-selling cancer drug, with a new subcutaneous version expected to attract more patients in the next two years, thereby sustaining sales growth and enhancing market competitiveness.
- Merck's Financial Performance: With a market cap of $285 billion and a current stock price of $118.32, Merck boasts a dividend yield of 2.88% and has increased its dividends by 93.8% over the past decade, demonstrating strong financial stability and long-term investment appeal.
- Novartis' Diversification Advantage: After losing patent exclusivity for Entresto, Novartis still managed revenue growth in 2025, with 15 of its medicines generating over $1 billion in annual sales, showcasing the depth of its product lineup and market adaptability.
- Novartis' Dividend Performance: Novartis has a market cap of $274 billion and a current stock price of $152.25, with a dividend yield of 3.17%, having raised its dividends every year since 1996, reflecting the safety and attractiveness of its dividend policy.
See More
Jim Cramer Updates Bullpen Watchlist with New Stocks
- New Additions: Jim Cramer added ARM Holdings and FedEx to the Bullpen, with ARM's recent in-house chip launch making it a bullish prospect at $161 per share, while FedEx, up about 30% this year, remains 'dramatically undervalued'.
- FedEx Restructuring: FedEx is spinning off its less-than-truckload unit, FedEx Freight, expected to complete by June 1, a move that typically creates more shareholder value, with Jim praising CEO Raj Subramaniam for navigating a competitive landscape effectively.
- Removed Stocks: Jim removed Airbnb and Marvell Technology from the watchlist, citing Airbnb's episodic performance as a concern, while Marvell's 57% rally in 2026 indicated a missed buying opportunity.
- Market Monitoring: Jim continues to monitor Sempra and RTX Corporation, with Sempra up over 8% year-to-date, while RTX could benefit from increased defense production, with Jim planning to decide post RTX's first-quarter results on April 21.
See More
Anthropic Appoints Novartis CEO to Board
- New Board Member: Generative AI startup Anthropic has appointed Novartis CEO Vas Narasimhan to its board, bringing expertise from overseeing the development and approval of over 35 medicines in a highly regulated industry, thereby enhancing the company's credibility in the biotech sector.
- AI in Drug Development: Narasimhan stated that AI is accelerating solutions to some of the toughest scientific challenges, deepening understanding of disease biology and designing better medicines, which will drive innovation for Anthropic in the healthcare space.
- Acquisition Activity: Anthropic acquired biotech startup Coefficient Bio earlier this month, further expanding its footprint in the biotech sector and indicating a strategic focus on the intersection of AI and biotechnology.
- IPO Prospects: Ahead of a potential initial public offering, Anthropic also appointed former Trump administration official Chris Liddell to its board in February, reflecting the company's proactive approach to capital market expansion and growth plans.
See More
Novartis Expands Heart Disease and Cancer Treatment Programs
- Program Expansion: Novartis announced the expansion of its heart disease and cancer treatment programs from 11 to over 30 countries, with plans to implement initiatives in five U.S. cities by 2030, addressing the slowdown in public health efforts against chronic diseases.
- Community Collaboration: Each program will involve partnerships with local organizations, health authorities, and private businesses to enhance access to prevention and early detection services, improve follow-up care, and expedite the referral process for specialist treatment, thereby better serving marginalized communities.
- Strategic Importance: This initiative not only reflects Novartis's commitment to addressing global health disparities but also aims to enhance patient outcomes and quality of life by strengthening community health systems, further solidifying its leadership position in the global pharmaceutical industry.
- Future Outlook: Novartis's expansion plan aligns with its commitment to achieving growth despite facing 'historic' patent cliffs, demonstrating the company's adaptability in response to innovation and changing market demands.
See More
SIDEWINDER THERAPEUTICS SECURES FUNDING WITH SUPPORT FROM FRAZIER LIFE SCIENCES AND NOVARTIS VENTURE FUND
Funding Announcement: The article discusses a new funding initiative in the therapeutics sector, co-led by major companies including Frazer Life Sciences and Novartis Venture Fund.
Investment Focus: The funding aims to support innovative therapeutic solutions, highlighting the growing interest and investment in healthcare advancements.
See More
Impact of Trump's Tariffs One Year Later
- Widespread Tariff Impact: Trump's tariff policies have placed significant economic pressure on U.S. businesses over the past year, with approximately 80% to 85% of costs absorbed by companies, leading to reduced profits and increased consumer prices, thereby exacerbating overall economic uncertainty.
- Retail Sector Adaptation: While large retailers like Walmart have emerged relatively unscathed, smaller businesses have been severely impacted, with Home Depot aiming to limit purchases from any single country to 10% to reduce dependency and enhance supply chain flexibility.
- Automotive Industry Cost Surge: Automakers such as General Motors and Toyota are facing tariff impacts estimated at up to $9.5 billion, and although the Trump administration has taken steps to alleviate overlapping tariffs, overall costs remain significant, forcing companies to reassess their supply chain strategies.
- Pharmaceutical Sector Stability: Pharmaceutical companies have secured three-year tariff exemptions through pricing agreements with Trump, although new tariffs impose 100% on companies that do not reach agreements, the overall industry is still striving to increase investments in U.S. manufacturing.
See More
Analysis of Dividend Stocks in the Pharmaceutical Industry
- Merck's Challenges and Opportunities: Despite declining sales of its HPV vaccines due to issues in Asia, Merck's Keytruda remains the world's best-selling cancer drug, with a new subcutaneous version expected to attract more patients in the next two years, thereby sustaining sales growth and enhancing market competitiveness.
- Merck's Financial Performance: With a market cap of $285 billion and a current stock price of $118.32, Merck boasts a dividend yield of 2.88% and has increased its dividends by 93.8% over the past decade, demonstrating strong financial stability and long-term investment appeal.
- Novartis' Diversification Advantage: After losing patent exclusivity for Entresto, Novartis still managed revenue growth in 2025, with 15 of its medicines generating over $1 billion in annual sales, showcasing the depth of its product lineup and market adaptability.
- Novartis' Dividend Performance: Novartis has a market cap of $274 billion and a current stock price of $152.25, with a dividend yield of 3.17%, having raised its dividends every year since 1996, reflecting the safety and attractiveness of its dividend policy.
See More
Jim Cramer Updates Bullpen Watchlist with New Stocks
- New Additions: Jim Cramer added ARM Holdings and FedEx to the Bullpen, with ARM's recent in-house chip launch making it a bullish prospect at $161 per share, while FedEx, up about 30% this year, remains 'dramatically undervalued'.
- FedEx Restructuring: FedEx is spinning off its less-than-truckload unit, FedEx Freight, expected to complete by June 1, a move that typically creates more shareholder value, with Jim praising CEO Raj Subramaniam for navigating a competitive landscape effectively.
- Removed Stocks: Jim removed Airbnb and Marvell Technology from the watchlist, citing Airbnb's episodic performance as a concern, while Marvell's 57% rally in 2026 indicated a missed buying opportunity.
- Market Monitoring: Jim continues to monitor Sempra and RTX Corporation, with Sempra up over 8% year-to-date, while RTX could benefit from increased defense production, with Jim planning to decide post RTX's first-quarter results on April 21.
See More
Anthropic Appoints Novartis CEO to Board
- New Board Member: Generative AI startup Anthropic has appointed Novartis CEO Vas Narasimhan to its board, bringing expertise from overseeing the development and approval of over 35 medicines in a highly regulated industry, thereby enhancing the company's credibility in the biotech sector.
- AI in Drug Development: Narasimhan stated that AI is accelerating solutions to some of the toughest scientific challenges, deepening understanding of disease biology and designing better medicines, which will drive innovation for Anthropic in the healthcare space.
- Acquisition Activity: Anthropic acquired biotech startup Coefficient Bio earlier this month, further expanding its footprint in the biotech sector and indicating a strategic focus on the intersection of AI and biotechnology.
- IPO Prospects: Ahead of a potential initial public offering, Anthropic also appointed former Trump administration official Chris Liddell to its board in February, reflecting the company's proactive approach to capital market expansion and growth plans.
See More
Novartis Expands Heart Disease and Cancer Treatment Programs
- Program Expansion: Novartis announced the expansion of its heart disease and cancer treatment programs from 11 to over 30 countries, with plans to implement initiatives in five U.S. cities by 2030, addressing the slowdown in public health efforts against chronic diseases.
- Community Collaboration: Each program will involve partnerships with local organizations, health authorities, and private businesses to enhance access to prevention and early detection services, improve follow-up care, and expedite the referral process for specialist treatment, thereby better serving marginalized communities.
- Strategic Importance: This initiative not only reflects Novartis's commitment to addressing global health disparities but also aims to enhance patient outcomes and quality of life by strengthening community health systems, further solidifying its leadership position in the global pharmaceutical industry.
- Future Outlook: Novartis's expansion plan aligns with its commitment to achieving growth despite facing 'historic' patent cliffs, demonstrating the company's adaptability in response to innovation and changing market demands.
See More
SIDEWINDER THERAPEUTICS SECURES FUNDING WITH SUPPORT FROM FRAZIER LIFE SCIENCES AND NOVARTIS VENTURE FUND
Funding Announcement: The article discusses a new funding initiative in the therapeutics sector, co-led by major companies including Frazer Life Sciences and Novartis Venture Fund.
Investment Focus: The funding aims to support innovative therapeutic solutions, highlighting the growing interest and investment in healthcare advancements.
See More
Impact of Trump's Tariffs One Year Later
- Widespread Tariff Impact: Trump's tariff policies have placed significant economic pressure on U.S. businesses over the past year, with approximately 80% to 85% of costs absorbed by companies, leading to reduced profits and increased consumer prices, thereby exacerbating overall economic uncertainty.
- Retail Sector Adaptation: While large retailers like Walmart have emerged relatively unscathed, smaller businesses have been severely impacted, with Home Depot aiming to limit purchases from any single country to 10% to reduce dependency and enhance supply chain flexibility.
- Automotive Industry Cost Surge: Automakers such as General Motors and Toyota are facing tariff impacts estimated at up to $9.5 billion, and although the Trump administration has taken steps to alleviate overlapping tariffs, overall costs remain significant, forcing companies to reassess their supply chain strategies.
- Pharmaceutical Sector Stability: Pharmaceutical companies have secured three-year tariff exemptions through pricing agreements with Trump, although new tariffs impose 100% on companies that do not reach agreements, the overall industry is still striving to increase investments in U.S. manufacturing.
See More
